Suppression of BRCA1 sensitizes to proteasome inhibitors in DNA repair-independent manner.
Ontology highlight
ABSTRACT: Germline and somatic mutations in BRCA1predispose to breast cancer. We found that proteasome inhibitors can selectively kill BRCA1-depleted cells. The toxic response involves a deregulation of the G1/S cell cycle checkpoint via hyperphosphorylation of RB1, 53BP1-mediated arrest at G2/M checkpoint, and ERN1-mediated unfolded protein response, culminating in a TNF receptor-mediated apoptosis. The study new unexpected molecular functions for BRCA1 protein and opens a novel possibility for the treatment of BRCA1-deficient cancers. We used microarrays to detail the global programme of gene expression underlying the response of BRCA1-deficient cells to proteasome inhibitor bortezomib. We aimed to identify genes that are strongly up- or down-regulated with a combination of BRCA1 knockdown and pr
ORGANISM(S): Homo sapiens
SUBMITTER: Dario Greco
PROVIDER: E-GEOD-56280 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA